Novavax, Inc. (NASDAQ: NVAX) on Friday, plunged -1.76% from the previous trading day, before settling in for the closing price of $9.92. Within the past 52 weeks, NVAX’s price has moved between $3.53 and $23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 513.29% over the past five years. The company achieved an average annual earnings per share of 81.38%. With a float of $153.03 million, this company’s outstanding shares have now reached $160.09 million.
Let’s look at the performance matrix of the company that is accounted for 1543 employees. In terms of profitability, gross margin is 59.57%, operating margin of -34.74%, and the pretax margin is -35.11%.
Novavax, Inc. (NVAX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Novavax, Inc. is 4.42%, while institutional ownership is 53.30%. The most recent insider transaction that took place on Sep 18 ’24, was worth 95,331. Before that another transaction happened on Jun 21 ’24, when Company’s Director sold 7,500 for $14.09, making the entire transaction worth $105,675. This insider now owns 61,760 shares in total.
Novavax, Inc. (NVAX) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.26 earnings per share (EPS) for the period topping the consensus outlook (set at -1.83) by 0.57. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 81.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to 11.55% growth over the previous five years of trading.
Novavax, Inc. (NASDAQ: NVAX) Trading Performance Indicators
Novavax, Inc. (NVAX) is currently performing well based on its current performance indicators. A quick ratio of 1.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach 0.04 in one year’s time.
Technical Analysis of Novavax, Inc. (NVAX)
Novavax, Inc. (NASDAQ: NVAX) saw its 5-day average volume 4.05 million, a negative change from its year-to-date volume of 10.05 million. As of the previous 9 days, the stock’s Stochastic %D was 8.34%. Additionally, its Average True Range was 0.86.
During the past 100 days, Novavax, Inc.’s (NVAX) raw stochastic average was set at 5.84%, which indicates a significant increase from 5.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.99% in the past 14 days, which was lower than the 103.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.22, while its 200-day Moving Average is $9.67. Nevertheless, the first resistance level for the watch stands at $9.94 in the near term. At $10.13, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.34. If the price goes on to break the first support level at $9.54, it is likely to go to the next support level at $9.33. Assuming the price breaks the second support level, the third support level stands at $9.14.
Novavax, Inc. (NASDAQ: NVAX) Key Stats
Market capitalization of the company is 1.56 billion based on 140,404K outstanding shares. Right now, sales total 983,710 K and income totals -545,060 K. The company made 415,480 K in profit during its latest quarter, and 162,380 K in sales during its previous quarter.
